Elevated matrix metalloproteinase‑9 expression is associated with COVID‑19 severity: A meta‑analysis.

Area of Science:

• Biochemistry
• Immunology
• Infectious Diseases

Background:

• Coronavirus Disease 2019 (COVID-19) poses significant global health challenges.
• Understanding biomarkers for COVID-19 severity is crucial for patient management.
• Matrix metalloproteinase-9 (MMP-9) is implicated in inflammatory processes.

Purpose of the Study:

• To evaluate the clinical significance of serum MMP-9 levels in COVID-19 patients.
• To correlate MMP-9 levels with disease severity and patient outcomes.

Main Methods:

• A meta-analysis of 12 studies involving 2,062 COVID-19 patients.
• Searched databases including PubMed, Web of Science, EMBASE, Cochrane, WANFANG, and CNKI.
• Compared serum MMP-9 levels across different patient subgroups (severe vs. non-severe, ARDS vs. non-ARDS, survivors vs. non-survivors, etc.).

Main Results:

• Serum MMP-9 levels were significantly higher in severe COVID-19 patients compared to non-severe cases.
• Elevated MMP-9 levels were observed in patients with Acute Respiratory Distress Syndrome (ARDS).
• Higher MMP-9 levels were also noted in patients with neurological syndromes and obese diabetic patients.

Conclusions:

• Serum MMP-9 levels are significantly associated with COVID-19 severity.
• MMP-9 may serve as a potential biomarker for predicting COVID-19 progression.
• Targeting MMP-9 could be a therapeutic strategy for improving COVID-19 patient prognosis.